Skip to main content

Full text of "USPTO Patents Application 09864621"

See other formats



PTO/SB/21 (08-03) 
Approved for use through 07/31/2006. 0MB 0651-0031 
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 



Under the Paperwork Reducton Ad of 1995, no persons are required to res 


^nd to a collection of information unless it displays a valid 0MB control number. 


TRAMQMITTAI 

1 rxMlilOIVil 1 1 ML. 

FORM 

(to be used for all correspondence after initial filing) 


Application Number 


09/864.621 


Filing Date 


May 23, 2001 


First Named Inventor 


H. Ralph SNODGRASS 


Art Unit 


1632 


Examiner Name 


S-L Chen 


Total Number of Pages in This Submission 8 + 7 ref. 


Attorney Docket Number 


441472000110 



ENCLOSURES (Check all that apply) 



SFee Transmittal Fomn plus duplicate for 
fee processing (2 pages) 

I [ Fee Attached 
I I Amendment/Reply 



□ 



After Final 



I [ Affidavits/declaration (s) 
I I Extension of Time Request 

[ I Express Abandonment Request 

0 Information Disclosure Statement (3 
pages) 

□ Certified Copy of Priority 
Document(s) 

□ Response to Missing Parts/ 
Incomplete Application 

□ Response to Missing Parts 
under 37 CFR1.52 or1.53 



I I Licensing-retated Papers 



I I Drawing(s) 

□■ 

I I Petition 

□ Petition to Convert to a 
Provisional Application 

□ Power of Attorney, Revocation 
Change oif Correspondence Address 

I I Terminal Disclaimer 
I I Request for Refund 
Q]cD. Number ofCD(s) 



Remarks 



□ 
□ 
□ 
□ 
□ 



After Allowance Communication 
to Group 

Appeal Communication to Board of 
Appeals and Interferences 

Appeal Communication to Group 
(Appeal Notice, Brief, Reply Brief) 

Proprietary Information 
Status Letter 

Other Enclosure(s) (please 
identify below): 

1. Fomi PTO-1449 plus copy 
(2 pages) 

2. Seven (7) references 

3. Return postcard 



SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT 



Firm 
or 

Individual name 



MORRISON & FOERSTER LLP (Customer No. 25226) 
CarolM->pruppi - 37,341 




I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in 
an envelope addressed to: Commissioner ^for Patent P,0. Bpx 1450, Alex^p^a, 222ia-1450, on the date shown below. 



Dated: February 23, 2004 



Signatun 



sr^for Patent P,0. Box 145C 




I M. Raskowitz) 



pa-863998 




PTO/S8/17(10-03) 
Approved for use through 7/31/2006. 0MB 0651-0032 
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 



FEE TRANSMITTAL 
for FY 2004 

Effective 10/01/2003, Patent fees are subject to annual revision. 


Complete if Known 


Application Number 


09/864,621 


Filing Date 


May 23, 2001 


First Named Inventor 


H. Ralph SNODGRASS 


Examiner Name 


S-L. Chen 


X Applicant claims small entity status. See 37 CFR 1 .27 


Art Unit 


1632 


TOTAL AMOUNT OF PAYMENT ($) 180.00 


Attorney Docket No. 


441472000110 



METHOD OF PAYMENT (check all that apply) 



□£? □» □""□n.™ 

S 



Deposit Account: 



03-1952 



Morrison & Foerster LLP 



Deposit 
Account 
Niunrtjer 

Deposit 
Account 
Name 

The D irector is authorized to: (ctieck all tha t apply) 

I X I Charge fee(s) indicated below | X | Credit any overpayments 

I X I Charge any additional fee(s) or any underpayment of fee(s) 

I I Charge fee(s) indicated below, except for the filing fee 
to the above-identified deposit account. 



FEE CALCULATION 



1. BASIC FILING FEE 

Large Entity Small Entity 





Fee 


Fee 


Fee 


Fee 


Fee Description 




Code 


{$) 


Code 


($) 






1001 


770 


2001 


385 


Utility filing fee 




1002 


340 


2002 


170 


Design filing fee 




1003 


530 


2003 


265 


Plant filing fee 


r 


1004 


770 


2004 


385 


Reissue filing fee 




1005 


160 


2005 


80 


Provisional filing fee 



Fee Paid 



SUBTOTAL (1) ($) 



0.00 



2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 

Extra Fee nnom 
Claims below Fee Paid 



Claims I 

Multiple Dependent 



Large Entity 



Fee Fee 

Code ($) 

1202 18 
1201 86 

1203 290 

1204 86 

1205 18 



1 -28" = 


1 0 H 


9 




|.-= 


1 ° \A 


43 1=1 






1 


145 1=1 


0 



Small Entity 



^($) Fee Description 

2202 9 Claims in excess of 20 

2201 43 Independent claims in excess of 3 

2203 145 Multiple dependent claim, if not paid 

2204 43 *• Reissue independent claims 

over original patent 

2205 9 ** Reissue claims in excess of 20 

and over original patent 



SUBTOTAL (2) QsT 



**or number previously paid, If greater; For Reissues, see above 



FEE CALCULATION (continued)! 



3. ADDITIONAL FEES 

Large Entity Small Entity 



^^f^ 0 3 2Q\i4 



Fee Fee 
Code ($) 



1051 
1052 
1053 



130 
50 
130 



1812 2.520 

1804 920* 

1805 1.840* 

1251 110 

1252 420 

1253 950 

1254 1.480 

1255 2,010 

1401 330 

1402 330 

1403 290 

1451 1.510 

1452 110 

1453 1.330 

1501 1,330 

1502 480 

1503 640 
1460 130 



1807 
1806 
8021 
1809 
1810 
1801 
1802 



50 
180 
40 
770 

770 
770 
900 



Code 

2051 



Fee 



Fee Description 

65 Surcharge - late filing fee or oath 



Fee Paid 



2052 25 Surcharge - late provisional filing fee or cover 
sheet 

1053 130 Non-English specrtcation 

1 81 2 2,520 For filing a request for ex parte reexamination 

1 804 920* ^^^^^^1^9 publication of SIR prior to 

Examiner action 

1805 1 840* ^^'^^^^''^9 publication of SIR after 

Examiner action 

2251 55 Extension for reply within first month 

2252 210 Extension for reply within second month 

2253 475 Extension for reply within third month 

2254 740 Extension for reply within fourth month 

2255 1 ,005 Extension for reply within ftflh month 

2401 165 Notice of Appeal 

2402 165 Filing a brief in support of an appeal 

2403 145 Request for oral hearing 

1 451 1,510 Petition to institute a public use proceeding 

2452 55 Petition to revive - unavoidable 

2453 665 Petition to revive - unintentional 

2501 665 Utility issue fee (or reissue) 

2502 240 Design issue fee 

2503 320 Plant issue fee 
1 30 Petitions to the Commissioner 
50 Processing fee under 37 CFR 1 . 1 7(q) 
180 Submission of Information Disclosure Stmt 



1460 
1807 
1806 
8021 



Recording each patent assignment per 
property (times number of properties) 
oofto nac Filing 3 Submission after final rejection 
2809 385 CFR 1.129(a)) 



2810 
2801 



385 



For each additional Invention to be 



examined (37CFR 1.129(b)) 
385 Request for Continued Examination (ROE) 



1 802 900 ^^^^^^^ expedited examination 
of a design application 



Other fee (specify) 



^Reduced by Basic Filing Fee Paid 



180.00 



SUBTOTAL (3) QsT 



180.CM) 




pa-863993 




PATENT 
Docket No. 441472000110 



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL" 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: 
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 2^ 2004. 




Hazel M. Raskowitz 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 



In the application of: 

H. Ralph SNODGRASS 

Serial No.: 09/864,621 

Filing Date: May 23, 2001 

For: TOXICITY TYPING USING 
EMBRYOID BODIES 



Examiner: S-L. Chen 
Group Art Unit: 1632 



03 



^004 



SUPPLEMENTAL INFORMATION DISCLOSURE 
STATEMENT UNDER 37 C.F.R. § L97 & 1.98 



Commissioner for Patents 
P.O. Box 1450 

Alexandria, Virginia 22313-1450 



Dear Sir: 



Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the 
above-identified application the docimients listed on the attached Form PTO-1449. Copies of the 
documents are also submitted herewith. The Examiner is requested to make these documents of 
record. 

03/0a/S004 HHERONEN 00000066 031952 09864681 ' 
01 FC:1606 180.00 Dfl 



pa-857682 



This Supplemental Information Disclosure Statement is submitted: 

I I With the application; accordingly, no fee or separate requirements are required. 

[n Before the mailing of a first Office Action after the filing of a Request for Continued 

Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 

1.97(e)(1) has been provided. 
I I Within three months of the application filing date or before mailing of a first Office 

Action on the merits; accordingly, no fee or separate requirements are required. 

How^ever, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided. 
^ After receipt of a first Office Action on the merits but before mailing of a final Office 

Action or Notice of Allowance. 

I I A fee is required. A check in the amount of is enclosed. 

^ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached 

to this submission in duplicate. 
r~| A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee 

is believed to be due. 

I hereby certify that no item of information was cited in a communication from a foreign 
patent office in a coimterpart foreign application or, to the best of my knowledge after making 
a reasonable inquiry, was knovm to any individual designated in 37 C.F.R. § 1.56(c) more than 
three months prior to the filing of this Information Disclosure Statement. 

O After mailing of a final Office Action or Notice of Allowance, but before payment of the 
issue fee. 

I I A Certification under 37 C.F.R. § 1 .97(e) is provided above and a check in the 

amount of is enclosed. 

I I A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal 

form (PTO/SB/17 is attached to this submission in duplicate.) 

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, 
indicating that the information has been considered and made of record herein. 



pa-857682 



2 



Serial No. 09/864,621 
Docket No. 441472000110 




^ The information contained in this Supplemental Information Disclosure Statement under 
37 C.F.R. § 1.97 and § 1 .98 is not to be construed as a representation that: (i) a complete search 
has been made; (ii) additional information material to the examination of this application does 
not exist; (iii) the information, protocols, results and the like reported by third parties are 
accurate or enabling; or (iv) the above information constitutes prior art to the subject invention. 

In the unlikely event that the transmittal form is separated from this document and the 
Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 
C.F.R. §1.17(p)) is required. Applicant petitions for any required relief including extensions of 
time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due 
in connection with the filing of this document to Deposit Account No. 03-1952 referencing 
441472000110 . However, the Commissioner is not authorized to charge the cost of the issue fee 
to the Deposit Account. 



Dated: February 23, 2004 



RespectfiiUy submitted. 




Morrison & Foerster LLP 
755 Page Mill Road 



Palo Alto, California 94304-1018 



Telephone: (650) 813-5777 
Facsimile: (650) 494-0792 



pa-857682 



3 



Serial No. 09/864,621 
Docket No. 441472000110 



FEB 2 6 20fK 



PTO/SB/08 (2-92) 
Sheet 1 of 1 



Form PT^449 

i^^Q^^RMATION DISCLOSURE CITATION 
IN AN APPLICATION 

(Use several sheets if necessary) 


Docket Number 441 7420001 10 


Application Number 09/864,621 


Applicant 

H. Ralph SNODGRASS 


Filing Date May 23, 2001 


Qj^ft^Unit 1632 


Mailing Date February 23, 2004 ^^^l^A 



03 



U.S. PATENT DOCUMENTS 



^004 



Examiner 
Initials 


Ref. 
No. 


Date 


Document No. 


Name 


Class 


Subclass 


Filing Date If 
Appropriate 


















FOREIGN PATENT DOCUMENTS 


Examiner 
Initials 


Ref. 
No. 


Date 


Document No. 


Country 


Class 


Subclass 


Translation 
YES NO 



















OTHER DOCUMENTS 



(including author, title. Date, Pertinent Pages, Etc.) 



Examiner 
Initials 


Ref. 
No. 


Title 




1. 


Carere, A. et al. (2002). "In Vitro Toxicology Methods: Impact on Regulation From Technical and 
Scientific Advancements," Toxicol Lett, 127(1-3): 153-160. 




2. 


Church, V. L. et al. (1999). "Different Effects of BMP Antagonists Noggin & Fetuin on the 
Osteogenic Differentiation of Human Marrow Mesenchymal Stem Cells/' 26th European Symposium 
on Calcified Tissue, Maastricht, The Netherlands, May 7-11, 1999, 64(1):S54, Abstract No. P-17. 




3. 


Davila, J. C. et al, (1998). "Predictive Value of In Vitro Model Systems In Toxicology," ^«ww i?ev. 
Pharmacol ToxicoX. 38:63-96. 




4. 


Ji, X. et al. (2000). "Patterns of Gene Expression Associated with BMP-2 -Induced Osteoblast and 
Adipocyte Differentiation of Mesenchymal Progenitor Cell 3T3-F442A," J, Bone Miner, Metab, 
18(3):132-139. 




5. 


Thomas, R. S. et al. (2003). "Application of DNA Microarrays For Predicting Toxicity and 
Evaluating Cross-Species Extrapolation," Toxicogenomics,. Editors: Inoue and Pennie, Springer- 
Verlag Tokyo: Tokyo Japan, pp 31-38. 




6. 


Tugwood, J. D. et al (2003). "Genomics and the Search for Novel Biomarkers in Toxicology," 
Biomarkers 8(2): 79-82. 




7. 


Waring, J. F. et al. (2002). "The Promise of Toxicogenomics," Cur. Opin, Mol Ther, 4(3):229-235. 



EXAMINER: 



DATE CONSIDERED: 



EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in 
conformance and not considered. Include a copy of this form with next communication to applicant. 

PTO/SB/08 (2-92) 

pa- 856952 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE